Neurologic clinical trial - Regeneron R3918-MG-2018

Neurologic

Status:

Open and enrolling

Combination approach to treating MG with Regeneron’s fully human monoclonal antibody to C5 (pozelimab) and the small interfering RNA targeting C5 (cemdisiran).

Drug

Regeneron’s fully human monoclonal antibody, small interfering RNA

Phase

Phase 3

Condition

Generalized Myasthenia Gravis Myasthenia Gravis

Keywords

Regeneron